• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Adrenocortical Carcinoma Treatment Market

    ID: MRFR/Pharma/5105-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    Adrenocortical Carcinoma Treatment Market Research Report Information By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), Therapy (Radiation Therapy and Others), End-User (Hospitals and Clinics and Others) -Forecast till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Adrenocortical Carcinoma Treatment Market Research Report – Forecast to 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Adrenocortical Carcinoma Treatment Market Summary

    The Global Adrenocortical Carcinoma Treatment Market is projected to grow significantly from 3.82 USD Billion in 2024 to 8.85 USD Billion by 2035.

    Key Market Trends & Highlights

    Global Adrenocortical Carcinoma Treatment Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 7.94 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 8.85 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 3.82 USD Billion, reflecting the current demand for effective treatment options.
    • Growing adoption of advanced treatment modalities due to increasing awareness of adrenocortical carcinoma is a major market driver.

    Market Size & Forecast

    2024 Market Size 3.82 (USD Billion)
    2035 Market Size 8.85 (USD Billion)
    CAGR (2025-2035) 7.94%

    Major Players

    Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO., Ltd., Hitachi, Ltd., NeuroLogica Corp., Digirad Corporation

    Adrenocortical Carcinoma Treatment Market Drivers

    Market Growth Projections

    Rising Healthcare Expenditure

    The Global Adrenocortical Carcinoma Treatment Market Industry is also benefiting from increasing healthcare expenditure across various regions. Governments and private sectors are investing more in healthcare infrastructure, which facilitates better access to advanced cancer treatments. For instance, countries with robust healthcare systems are allocating significant budgets for oncology, thereby enhancing the availability of cutting-edge therapies for ACC. This trend is expected to drive market growth as more patients gain access to necessary treatments. The anticipated market value of 3.82 USD Billion in 2024 reflects this growing investment in healthcare.

    Emergence of Personalized Medicine

    The emergence of personalized medicine is reshaping the Global Adrenocortical Carcinoma Treatment Market Industry. Tailoring treatment plans based on individual genetic profiles and tumor characteristics allows for more effective and targeted therapies. This approach not only enhances treatment efficacy but also minimizes adverse effects, leading to improved patient satisfaction. As research continues to uncover the genetic underpinnings of ACC, the integration of personalized medicine into treatment protocols is expected to gain momentum. This trend aligns with the overall growth of the market, which is projected to reach 8.85 USD Billion by 2035.

    Advancements in Treatment Modalities

    Innovations in treatment modalities are significantly influencing the Global Adrenocortical Carcinoma Treatment Market Industry. The development of targeted therapies and immunotherapies has shown promise in improving patient outcomes. For instance, the introduction of drugs such as mitotane and novel immunotherapeutic agents has provided new avenues for treatment. These advancements not only enhance survival rates but also reduce the side effects associated with traditional therapies. As these treatment options become more widely available, the market is likely to witness substantial growth, with a projected compound annual growth rate (CAGR) of 7.94% from 2025 to 2035.

    Growing Awareness and Education Initiatives

    Growing awareness and education initiatives regarding adrenocortical carcinoma are playing a crucial role in the Global Adrenocortical Carcinoma Treatment Market Industry. Organizations and healthcare providers are increasingly focusing on educating both the public and healthcare professionals about the signs and symptoms of ACC. This heightened awareness leads to earlier diagnosis and treatment, which is essential for improving patient outcomes. As more individuals become informed about ACC, the demand for effective treatment options is likely to rise, contributing to the market's projected growth trajectory.

    Increasing Incidence of Adrenocortical Carcinoma

    The Global Adrenocortical Carcinoma Treatment Market Industry is experiencing growth due to the rising incidence of adrenocortical carcinoma (ACC). Recent statistics indicate that ACC is a rare but aggressive cancer, with an estimated annual incidence of 0.5 to 2 cases per million people. As awareness increases and diagnostic techniques improve, more cases are being identified, leading to a greater demand for effective treatment options. This trend is expected to contribute to the market's expansion, with projections indicating a market value of 3.82 USD Billion in 2024, potentially reaching 8.85 USD Billion by 2035.

    Key Companies in the Adrenocortical Carcinoma Treatment Market market include

    Future Outlook

    Adrenocortical Carcinoma Treatment Market Future Outlook

    The Global Adrenocortical Carcinoma Treatment Market is projected to grow at a 7.94% CAGR from 2024 to 2035, driven by advancements in targeted therapies and increasing awareness.

    New opportunities lie in:

    • Develop personalized treatment plans leveraging genomic profiling.
    • Invest in innovative drug delivery systems to enhance efficacy.
    • Expand clinical trial networks to accelerate drug approvals.

    By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment options and improved patient outcomes.

    Market Segmentation

    Intended Audience

    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market, by Type

    • Metastatic Adrenocortical Carcinoma
    • Localized Adrenocortical Carcinoma
    • Others
    • Adjuvant Therapy
    • Brachytherapy
    • External beam radiation therapy
    • Radiation Therapy
    • Targeted Therapy
    • Chemotherapy
    • Open surgery
    • Laparoscopic surgery
    • Surgery
    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market, by Region

    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market Key Players

    • and Digirad Corporation 
    • NeuroLogica Corp.
    • Hitachi, Ltd.
    • Sinovision Technologies (Beijing) CO., Ltd.
    • Fresenius Kabi AG
    • Mylan N.V.
    • WG Critical Care, LLC
    • General Electric Company
    • Bristol-Myers Squibb Company
    • HRA Pharma
    • Orphagen Pharmaceuticals, Inc.
    • Merck & Co.
    • Millendo Therapeutics, Inc.
    • Exelixis, Inc.
    • EnGeneIC Ltd
    • Pfizer Ltd.
    • Arqule

    Adrenocortical Carcinoma Treatment Market, by Therapy

    • Others
    • Adjuvant Therapy
    • Brachytherapy
    • External beam radiation therapy
    • Radiation Therapy
    • Targeted Therapy
    • Chemotherapy
    • Open surgery
    • Laparoscopic surgery
    • Surgery
    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market, by End-User

    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market Regional Analysis

    • Metastatic Adrenocortical Carcinoma
    • Localized Adrenocortical Carcinoma
    • Others
    • Adjuvant Therapy
    • Brachytherapy
    • External beam radiation therapy
    • Radiation Therapy
    • Targeted Therapy
    • Chemotherapy
    • Open surgery
    • Laparoscopic surgery
    • Surgery
    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 3.65 (USD Billion)
    Market Size 2024 3.82 (USD Billion)
    Market Size 2032 8.17 (USD Billion)
    Compound Annual Growth Rate (CAGR) 2.72 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors  Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO. Ltd. Hitachi Ltd. NeuroLogica Corp., and Digirad Corporation
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers Increase in prevalence rates of rare cancers Increased focus of companies on the treatment of adrenocortical carcinomas

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What would be the CAGR for Adrenocortical Carcinoma Treatment market during the forecast period of 2024-2032?

    The CAGR for Adrenocortical Carcinoma Treatment market would be 2.72% during the forecast period.

    What could prevent Adrenocortical Carcinoma Treatment market growth?

    Lack of oncology experts and high risk of local occurrence and different metastatic progress can deter Adrenocortical Carcinoma Treatment market growth.

    What are types discussed in the Adrenocortical Carcinoma Treatment market report?

    The types included in Adrenocortical Carcinoma Treatment market report are localized adrenocortical carcinoma and metastatic adrenocortical carcinoma.

    Which region would dominate the Adrenocortical Carcinoma Treatment market?

    The Americas would dominate the Adrenocortical Carcinoma Treatment market.

    Which region would be the fastest-growing in the Adrenocortical Carcinoma Treatment market?

    The APAC region would dominate Adrenocortical Carcinoma Treatment market in terms of growth rate.

    Adrenocortical Carcinoma Treatment Market Research Report – Forecast to 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials